Key result
SR-B1 expression was significantly higher in liposarcomas (69.2%) compared to non-lipomatous sarcomas (4.9%, p=0.000), indicating its potential as a diagnostic biomarker.
Why the study?
SR-B1 is linked to malignancy and poor prognosis in various cancers, but its expression in soft tissue sarcomas had not been assessed.
Observational (n=107)
No
Absolute Event Rate: 69.2% vs 4.9%
p-value: p=0.000
SR-B1 is highly expressed in liposarcomas compared to non-lipomatous sarcomas and may serve as a potential diagnostic biomarker and indicator of differentiation.
SR-B1 expression in sarcomas leaves open its prognostic utility; prospective validation required before any clinical consideration.
Background: Soft tissue sarcomas include multiple histological subtypes and are highly aggressive. Moreover, SR-B1 is associated with malignant behavior and poor prognosis in a variety of cancers. However, there have been no attempts to assess whether SR-B1 expression in soft tissue sarcoma. We aimed to detect the expression levels of the SR-B1 protein in soft tissue sarcoma. Methods: We assessed SR-B1 expression via immunohistochemistry and tissue microarrays in 107 soft tissue sarcomas with 4 phenotypes: 26 liposarcomas, 18 Ewing's sarcomas, 20 rhabdomyosarcomas and 43 leiomyosarcomas. Results: Tumor cell SR-B1 expression was seen in 18/26 (69.2%) liposarcomas, 1/18 (5.55%) Ewing's sarcomas, 1/20 (5.00%) rhabdomyosarcomas, 2/43 (4.70%) leiomyosarcomas and was stained in the cell membrane. We found that SR-B1 expression in liposarcomas (18/26) was significantly higher than that in non-lipomatous sarcomas (4/77) (2 = 49.811, p = 0.000) and in well-differentiated liposarcoma (13/15) was significantly higher than that in dedifferentiated liposarcoma (5/11) (p = 0.038). No significant correlation was found between SR-B1 and gender, nationality, size and tumor location (p > 0.05), but it was significantly associated with ages (2 = 11.426, p = 0.001) and sarcoma phenotypes (2 = 49.817, p = 0.000). Conclusion: Our findings highlight the highly expression of SR-B1 in liposarcomas. SR-B1 may be a potential biomarker for the diagnosis of liposarcoma and may indicate the degree of differentiation of liposarcomas.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) conducted an observational in Soft tissue sarcoma (n=107). Liposarcoma vs. Non-lipomatous sarcomas was evaluated on Positive SR-B1 protein expression (p=0.000). SR-B1 expression was significantly higher in liposarcomas (69.2%) compared to non-lipomatous sarcomas (4.9%, p=0.000), indicating its potential as a diagnostic biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: